

**PRESS RELEASE**  
**FOR IMMEDIATE RELEASE**

**PHARMANIAGA STRENGTHENS ESG AND SUSTAINABILITY  
INITIATIVES THROUGH DECARBONISATION PROGRAMME**

**SHAH ALAM, 10 DECEMBER 2022** – Malaysia's leading pharmaceutical company, Pharmaniaga Berhad (Pharmaniaga) continues paving the way to embrace Environment, Social and Governance (ESG) as well as sustainability initiatives across its business operations, in line with the Government's Low Carbon Aspiration 2040.

Pharmaniaga Group Managing Director Datuk Zulkarnain Md Eusope said as one of the largest pharmaceutical and Government-linked companies in Malaysia, the Group is aware of its responsibilities and impact on the environment as well as the communities.

"We believe our overall ESG and sustainability efforts will ultimately translate to improved processes that will enhance our financial performance and ensure business sustainability," he said.

Datuk Zulkarnain said the Group has embarked on decarbonisation programmes as part of its support to the Government's mission of achieving zero net carbon emission by 2050.

"One of our major initiatives includes the use of electric vehicles to deliver medicines to Government hospitals and clinics in order to reduce the Group's overall Greenhouse Gas (GHG) emissions.

"The programme is progressing well. Site visits to our subsidiaries have been conducted to develop a long-term sustainability roadmap and initiatives. Areas identified through the programme include energy efficiency, renewable energy and the use of electric vehicles.

"As required by Bursa Malaysia, all Main Market listed issuers will be made mandatory to report Task Force on Climate-related Financial Disclosure by 2025. Bursa will be internalising climate change considerations in business strategies as well as in responding to the needs of its key stakeholders.

"To prepare for the direction from Bursa, we have planned various initiatives to mitigate the matters related to climate change by including Environmental Sustainability Risk in the company's Enterprise Risk Management and Board's oversight of all climate change-related matters; risk, opportunity and mitigation plans," said Datuk Zulkarnain.

Recently, the Group is in the midst of registering with United Nations Global Compact (UNGC) to further strengthen its ESG programme as well as to enhance our commitment and involvement internationally.

Another plan in the pipeline is to inculcate a sustainability culture to rebrand the Group's existing Do It Right Always (DIRA) internal corporate culture to raise awareness levels amongst its employees on the importance of 'Doing the Right Thing' every time to increase the level of productivity and work efficiency by eliminating the need for rework.

"We are in the progress of rebranding the existing DIRA culture to include ESG elements. This initiative aims to ingrain a sustainability mindset in all employees by reinforcing the existing campaigns and at the same time, introducing new campaigns. DIRA will represent initiatives under ESG, which are the key pillars of sustainability. It is important for all employees to understand sustainability to ensure we achieve our long-term sustainability goals for the Group," Datuk Zulkarnain added.

Alongside this, the Group recently received the silver award for "Best Performing Company by Bursa Sector Classification: Healthcare" at The EDGE ESG Awards 2022 for its ongoing efforts in promoting and incorporating ESG and sustainability initiatives throughout its operations.

The award was received by Pharmaniaga Executive Director Zulkifli Jafar from The Edge Malaysia Editor-in-Chief Kathy Fong; and witnessed by Chief Executive Officer of Bursa Malaysia Datuk Muhamad Umar Swift; Chief Executive Officer of UOB Malaysia Ng Wei Wei; Asia-Pacific Head of Sustainable Investments at FTSE Russell Helena Fung; and Publisher and Group Chief Executive Officer of The Edge Media Group Datuk Ho Kay Tat.

The Edge Malaysia ESG Awards, which comprises two categories — the Equity Awards and the Fund Awards, aims to honour Malaysia's best performers in ESG excellence. It was organised in collaboration with Bursa Malaysia and FTSE Russell, with Morningstar as the knowledge partner for the funds' category and Deloitte as the auditor.

Pharmaniaga is the pharmaceutical Company of Boustead Holdings Berhad group of companies, and together with Lembaga Tabung Angkatan Tentera, are the major shareholders of the Company.

-END-

---

**About Pharmaniaga Berhad (Pharmaniaga)**

Pharmaniaga is the pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of Pharmaniaga. Listed on the Main Market of Bursa Malaysia Securities Berhad, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy.

With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga is positioned to be a regional player in the international pharmaceutical arena.

For more information, please log on to <https://pharmaniaga.com/>.

**Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad. For media enquiries, please contact Dato' Najmuddin Abdullah at 019-3387777, email, najmuddin@pharmaniaga.com or Dato' Zuhri Iskandar Kamarzaman at 03-3342 9999 ext 434 or email zuhri@pharmaniaga.com.**